Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 2,534 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Janet Jill Hopkins sold 2,534 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total value of $19,638.50. Following the sale, the insider now directly owns 269,794 shares in the company, valued at approximately $2,090,903.50. The trade was a 0.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Aura Biosciences Price Performance

NASDAQ AURA traded down $0.12 during trading on Friday, hitting $7.51. The company's stock had a trading volume of 146,728 shares, compared to its average volume of 138,951. The business's 50 day simple moving average is $7.99 and its 200-day simple moving average is $8.73. The company has a market cap of $375.12 million, a PE ratio of -4.34 and a beta of 0.29. Aura Biosciences, Inc. has a fifty-two week low of $6.63 and a fifty-two week high of $12.38.

Analyst Upgrades and Downgrades

Several analysts have commented on AURA shares. Lifesci Capital raised shares of Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. HC Wainwright reissued a "buy" rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Aura Biosciences presently has an average rating of "Buy" and a consensus price target of $23.00.

Institutional Trading of Aura Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Long Focus Capital Management LLC increased its holdings in shares of Aura Biosciences by 123.9% in the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock valued at $20,861,000 after purchasing an additional 1,404,228 shares during the period. Vanguard Group Inc. boosted its position in Aura Biosciences by 6.2% in the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company's stock valued at $15,764,000 after buying an additional 112,296 shares during the last quarter. Franklin Resources Inc. increased its holdings in Aura Biosciences by 3.2% in the 4th quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company's stock worth $14,164,000 after buying an additional 54,103 shares during the period. Levin Capital Strategies L.P. raised its position in Aura Biosciences by 169.1% during the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock worth $10,255,000 after buying an additional 783,984 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company's stock valued at $8,327,000 after acquiring an additional 3,972 shares during the period. Institutional investors and hedge funds own 96.75% of the company's stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.